Basal insulin analogues in people with diabetes and chronic kidney disease.

David León Jiménez José Pablo Miramontes GonzálezLaura Márquez-LópezFrancisco Astudillo-MartínLuis M Beltrán-RomeroFernando Moreno-ObregónJavier Escalada-San Martín

Published in: Diabetic medicine : a journal of the British Diabetic Association (2021)

Basal insulins are safe and effective in patients with CKD and diabetes mellitus but we do not have specific studies. Given that CKD is one of the main complications of type 2 DM, and insulin specific treatment in the final stages, the absence of studies is striking. Real-life data are also important since trials such as pivotal studies do not fully represent actual patients. Treatment should be individualized until we have specific trials in this type of population.

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
glycemic control
cardiovascular disease
case control
peritoneal dialysis
ejection fraction
risk factors
molecular docking
metabolic syndrome
skeletal muscle
deep learning
replacement therapy
patient reported outcomes
structure activity relationship